Lite Strategy Inc Com Par $ (LITS:NASDAQ) closed at $1.16 on October 23, 2026, down 2.52% on the day. The stock trades 48.7% below its 52-week high of $2.26 and 68.1% above its 52-week low of $0.690. Over the past year, it lost 40.2%. Lite Strategy Inc Com Par $ is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, LITS closed higher on 108 days (43%). Its best day was September 24, 2026 (+21.19%) and its worst was June 2, 2026 (-14.58%). The stock moved 10% or more in a single session 11 times.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Find more stocks like LITS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.